Omega Diagnostics (GB:CNSL) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cambridge Nutritional Sciences reports a boost in profitability with an improved gross margin of 65.4% and an increase in adjusted EBITDA to £0.2m for the first half of 2024, despite a 16% drop in revenue. The company attributes its success to operational efficiencies and is focusing on expanding its sales team and market outreach, particularly in the UK and the USA, to drive future growth. With a solid cash position of £4.5m, CNS is well-positioned to meet its strategic objectives and enhance its market presence.
For further insights into GB:CNSL stock, check out TipRanks’ Stock Analysis page.
